Počet záznamů: 1
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
- 1.
SYSNO ASEP 0577353 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death Tvůrce(i) Sarkar, A. (IN)
Novohradský, Vojtěch (BFU-R) ORCID
Maji, M. (IL)
Babu, T. (IL)
Marková, Lenka (BFU-R) ORCID
Kostrhunová, Hana (BFU-R) RID, ORCID
Kašpárková, Jana (BFU-R) RID, ORCID
Gandin, V. (IT)
Brabec, Viktor (BFU-R) RID, ORCID
Gibson, D. (IL)Celkový počet autorů 10 Zdroj.dok. Angewandte Chemie - International Edition. - : Wiley - ISSN 1433-7851
Roč. 62, č. 42 (2023)Poč.str. 12 s. Forma vydání Online - E Jazyk dok. eng - angličtina Země vyd. DE - Německo Klíč. slova Doxorubicin ; Gemcitabine ; Immunogenic Cell Death ; Multi-Targeting Prodrugs ; Oxaliplatin Vědní obor RIV EC - Imunologie Obor OECD Immunology CEP GA23-06307S GA ČR - Grantová agentura ČR Způsob publikování Open access Institucionální podpora BFU-R - RVO:68081707 UT WOS 001063194900001 EID SCOPUS 85170356579 DOI 10.1002/anie.202310774 Anotace A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s, it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin. Pracoviště Biofyzikální ústav Kontakt Jana Poláková, polakova@ibp.cz, Tel.: 541 517 244 Rok sběru 2024 Elektronická adresa https://onlinelibrary.wiley.com/doi/epdf/10.1002/anie.202310774
Počet záznamů: 1